Last reviewed · How we verify
IC51 Japanese Encephalitis
IC51 is an inactivated Japanese encephalitis virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus.
IC51 is an inactivated Japanese encephalitis virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus. Used for Prevention of Japanese encephalitis in adults and children.
At a glance
| Generic name | IC51 Japanese Encephalitis |
|---|---|
| Sponsor | Valneva Austria GmbH |
| Drug class | Inactivated viral vaccine |
| Target | Japanese encephalitis virus |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
IC51 contains inactivated Japanese encephalitis virus particles that trigger both humoral (antibody) and cell-mediated immune responses. The vaccine is designed to provide protection against infection by Japanese encephalitis virus, a flavivirus transmitted by mosquitoes in Asia and the Western Pacific region. By priming the immune system, the vaccine aims to prevent symptomatic infection and severe disease.
Approved indications
- Prevention of Japanese encephalitis in adults and children
Common side effects
- Injection site pain or erythema
- Headache
- Myalgia
- Fatigue
Key clinical trials
- Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51 (PHASE3)
- Safety and Tolerability of the Japanese Encephalitis Vaccine IC51 (PHASE3)
- Immunogenicity Study of the Japanese Encephalitis Vaccine IC51 (PHASE3)
- Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population (PHASE3)
- Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries (PHASE3)
- Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study (PHASE3)
- Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling (PHASE3)
- Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IC51 Japanese Encephalitis CI brief — competitive landscape report
- IC51 Japanese Encephalitis updates RSS · CI watch RSS
- Valneva Austria GmbH portfolio CI